Skip to content

Person-checked company records fromPerson-checked records $750See a worked exampleHuman review in progress

Talk to sales

KeptIndex

Denali Therapeutics Inc.

Report 24-week data from Cohort A of the Phase 1/2 study of DNL310

Delivered after the deadline (25 days after the deadline)

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced
11 Jan 2021
Due
30 Jun 2021
Delivered
25 Jul 2021
  • Deadline
  • Met
  • Late
  • Not met
  • Today

What the company said

“Mid 2021 ETV:IDS (DNL310) Hunter syndrome (MPS II) 24-week data from Cohort A of Phase 1/2 study”

What we found

Evidence strength A What the grades mean

The company reported 6-month (24-week) data for DNL310 in July 2021, which occurred shortly after the mid-2021 deadline.

  • A
    Denali Therapeutics Inc. 8-K filed 2021-08-04 Regulatory filing · published 4 Aug 2021 · retrieved 24 Oct 2026 · kept permanently by the SEC · fingerprint 0ebe8da46510
    “In July 2021, Denali announced longer-term safety data and 6-month biomarker data on DNL310 from Cohort A in a Phase 1/2 study in patients with Hunter syndrome.” ✓ confirmed on the page

Market reaction: the shares moved +1.5% against the S&P 500 over the three sessions around the disclosure (3 Aug 2021 to 6 Aug 2021). What this measures

Checked 24 Oct 2026.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type
Clinical readout
Indicative materiality
Medium rules
Action
Report
Deliverable
DNL310 24-week data
In the company’s control
High
Specificity
High

How this entry was checked

  1. Commitment recordedThe company's words were matched word for word against the filing.
  2. First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
  3. Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you Denali Therapeutics Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2021-DNLI-021861 · Corrections policy

The Deadline Report

One email a week: the corporate commitments that came due, which were met, which slipped, and what is due next. Free. Stop any time.

No advertising. We never sell or share your address.